linjc16/ctgov huggingface dataset:
Database for Interstitial Lung Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.

Official Title
-----------------
Clinical Database for the Early Recognition of Pulmonary Parenchymal Involvement in Patients With Systemic Diseases Bearing a Risk for Interstitial Lung Disease

Conditions
-----------------
Lung Diseases, Interstitial

Intervention / Treatment
-----------------
* Diagnostic Test: chest CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: ≥ 18 years patients with a known systemic disease bearing a risk for ILD signed informed consent (for prospective part) Exclusion Criteria: Age < 18 years comorbidities severely limiting life-expectancy (e.g. severe cardiovascular conditions, malignant disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| prospective patient cohort<br>patients who will undergo the prospective ILD Screening algorithm | Diagnostic Test: chest CT<br>* assessment of interstitial lung disease using chest CT<br>|
| retrospective patient cohort<br>patients with diagnosed ILD | Diagnostic Test: chest CT<br>* assessment of interstitial lung disease using chest CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DLCO%pred (carbon monoxide diffusing capacity) at time of ILD diagnosis | The investigators aim to assess DLCO% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the DLCO%pred at time of ILD diagnosis | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FVC%pred (Forced vital capacity) at time of ILD diagnosis | The investigators aim to assess FVC% pred at time of ILD diagnosis in patients undergoing a ILD Screening algorithm and compare to the retrospective patient cohort with diagnosed ILD and the FVC%pred at time of ILD diagnosis | 5 years |
Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

Study Overview
=================
Brief Summary
-----------------
Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Detailed Description
-----------------
We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Official Title
-----------------
A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use

Conditions
-----------------
Adrenergic Pathology

Intervention / Treatment
-----------------
* Drug: Administration of 123Iodine MIBG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with potential Adrenergic pathology Exclusion Criteria: Pregnant or breast feeding females Hypersensitivity to MIBG

Ages Eligible for Study
-----------------
Minimum Age: 1 Month

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Administration of 123Iodine MIBG to the patients referred . | Drug: Administration of 123Iodine MIBG<br>* Patients will be administered the locally produced 123 Iodine MIBG<br>* Other names: None applicable;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety profile of the 123Iodine MIBG |  | BP and Heart rate for 24 hours after injection. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety profile, locally produced 123 Iodine MIBG
Efficacy Vulvovaginitis Candida

Study Overview
=================
Brief Summary
-----------------
To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp.

Detailed Description
-----------------
Multi-center, open-label, randomized study, controlled with fluconazole.

Official Title
-----------------
A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis

Conditions
-----------------
Candidiasis Vulvaginitis

Intervention / Treatment
-----------------
* Drug: Albaconazole oral solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory patients over 18 years of age, with a vaginal score sum ³ 2 and KOH fresh examination positive for yeasts (hyphae, pseudohyphae). The diagnosis must be later confirmed with a positive Candida spp. culture. Exclusion Criteria: Patients with recurrent disease, prior treatment with antifungal agents within the last 7 days, immunosuppression, pregnant or lactating women, other vulvovaginal diseases, other systemic diseases, hypersensitivity to azole derivatives.Number of patients: 78 patients included to obtain 60 evaluable patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Albaconazole oral solution|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Efficacy VariableThe primary efficacy assessment will be carried out 24 ± 4 (FV) days following treatment or at the last patient's. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antifungal oral therapy, efficacy acute candidiasis vulvaginitis
A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck

Study Overview
=================
Brief Summary
-----------------
This is a randomized study of conventional 3d radiation versus intensity-modulated radiation in squamous cell cancer of the head and neck.

Official Title
-----------------
A Randomized Phase II Study of Conventional 3D Radiation (3DCRT) Versus Intensity-Modulated Radiation (IMRT) in Squamous Cell Cancer of the Head and Neck (SCCHN): Pilot Feasibility Study

Conditions
-----------------
Head and Neck Neoplasms, Squamous Cell Cancer

Intervention / Treatment
-----------------
* Procedure: Intensity Modulated Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically proven squamous cell carcinoma of the head and neck or squamous cell cancer to the neck from an unknown head and neck primary site, stage I-IV disease which is M0, age greater than 18 years, KPS greater than 70, signed study-specific consent Exclusion Criteria: M1; bilateral N3 disease; primary greater than 10cm; salivary gland disease; life expectancy less than 2 years; prior radiotherapy to the head and neck; no signed study-specific consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Intensity Modulated Radiotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence and severity of side effects according to Radiation Therapy Oncology Group |  |  | 
| scales and CTCAE version 3.0 for acute and chronic radiation toxicities, local control rates |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
head and neck neoplasms, squamous cell cancer, intensity modulated radiotherapy
The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor

Study Overview
=================
Brief Summary
-----------------
Currently, the study about intervention on the induced abortion at trimester is so little. So, the investigators want to compare the safety and effectiveness of different induced labor.

Detailed Description
-----------------
In this study , the investigators want to compare the safety and effectiveness of different induced labor. The safety and effectiveness such as the success rate of induced labor and the gestation outcome,etc.

Official Title
-----------------
The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor

Conditions
-----------------
Labor; Forced or Induced, Affecting Fetus or Newborn

Intervention / Treatment
-----------------
* Other: Cook Balloon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestation age ≥37week Single fetus No serious complications Exclusion Criteria: Gestation age <37week Multiple fetus With serious complications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: oxytocin<br>There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon. This group is term gestaion,with bishop score less than 6. | Other: Cook Balloon<br>* There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon. This group is term gestaion,with bishop score less than 6.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The success rate of induced labor |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxytocin, Cook Balloon
Neurectomy Vs Nerve Sparing in Open Inguinal Hernia Repair

Study Overview
=================
Brief Summary
-----------------
It is a randomized controlled trial in which we are treating inguinal hernia patients with mesh hernioplasty and either neurectomy of iliohypogastric nerve and ilioinguinal neurectomy or preservation comparing post operative acute or chronic pain

Official Title
-----------------
Neurectomy Vs Nerve Sparing in Open Inguinal Hernia Repair

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: Neurectomy in inguinal hernia repair
* Procedure: nerve sparing in inguinal hernia repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients male, and age between 20 to 70 years Reducible inguinal hernia Exclusion Criteria: Irreducible, obstructed or strangulated hernia uncontrolled diabetes

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Neurectomy<br>In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve | Procedure: Neurectomy in inguinal hernia repair<br>* Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve<br>|
| Active Comparator: Nerve Sparing<br>In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve | Procedure: nerve sparing in inguinal hernia repair<br>* Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients developing chronic inguinodynia | Excruciating Pain measured by visual analog score (with 1 being minimum score and 10 being maximum score) for more than 3 months in inguinal region after open mesh hernioplasty for inguinal hernia | 3 months |
Prevalence of Medical Care in an Emergency Structure of the Women Victims of Violence Within the Couple

Study Overview
=================
Brief Summary
-----------------
Violence against women within the couple is a major socio-political and public health problem. Indeed, in 2020, 219,000 women were victims of violence within their couple and 102 women were killed by their partner or ex-partner. On average, the number of women aged 18 to 75 who in the course of a year are victims of rape and/or attempted rape is estimated at 94,000 women, and in 47% of cases it is the spouse or the ex-spouse who is the author of the facts. This violence has major health and social consequences: the leading cause of death and disability among women aged 16 to 44 in Europe. In France, a woman dies as a result of domestic violence every 2.5 days and the overall cost of domestic violence in 2012 amounted to 3.6 billion euros in France. A better knowledge of the use of care for wives of victims of violence and their feelings vis-à-vis the medical care in an emergency service will make it possible to identify the problems related to their care based on their feelings. of these patients, to understand why they would not have consulted as a first resort if necessary and to subsequently propose avenues for improvement.

Official Title
-----------------
Prevalence of Medical Care in an Emergency Structure and Expectations Vis-à-vis the Care System Among Women Victims of Violence Within the Couple Treated in the Associative, Social and Medico-legal Environment

Conditions
-----------------
Spousal-Abuse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult women (age ≥ 18 years old) victims of violence committed within the couple Initial visit to the emergency room or not Subject not opposed to participating in the study Exclusion Criteria: Intra-family violence committed by a parent, outside the couple (for example: father, grandfather, brother, cousin, uncle, child) Impossibility of giving informed information to the subject (subject in an emergency situation, difficulties in understanding the subject, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of recourse to care in an emergency structure among women cared for in a reception center for women victims of violence |  | from January 01, 2012 to December 31, 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spousal-Abuse, Violence against women
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma

Study Overview
=================
Brief Summary
-----------------
Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly asymptomatic, it is still associated with a pain syndrome especially if encroaches into the neural canal. This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults with spinal hemangioma.

Official Title
-----------------
The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study

Conditions
-----------------
Spinal Tumor, Spinal Hemangioma, Beta Blocker Toxicity

Intervention / Treatment
-----------------
* Drug: Atenolol Pill
* Drug: Propranolol Pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: vertebral hemangioma Exclusion Criteria: symptomatic bradycardia AV block decompensated heart failure asthma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Previously treated + Atenolol<br>The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately | Drug: Atenolol Pill<br>* Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.<br>|
| Active Comparator: Previously treated + Propranolol<br>The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately | Drug: Propranolol Pill<br>* Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing tumor growth | MRI | 3 months | 
| Reducing tumor | MRI | 6 months | 
| Life-quality | Valid questionnaires based on the ones, approved by EuroQol Organization | 3 months and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
β-blockers, Vertebral Hemangioma, Efficacy
Treatment Clinical Practice in Bipolar Depression in Spain

Study Overview
=================
Brief Summary
-----------------
Cross-sectional observational, non interventional, multicenter study of retrospective review of clinical records of ambulatory followed up bipolar patients in order to record epidemiological aspects of the course of the disorder, more specifically of bipolar depression episodes and the clinical practices carried out by psychiatrists in Spain in bipolar depressive episodes

Official Title
-----------------
EPIDEP. Epidemiologic Study in Bipolar Depression: Evaluation of the Usual Clinical Practice of Psychiatrists in Spain

Conditions
-----------------
Bipolar Depression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed of Bipolar Disorder I or II (DSM-IV-TR) in ambulatory follow-up Evolution of the bipolar diagnoses inferior to 10 years Having recorded in the patient's clinical history the clinical management of at least two bipolar depressive episodes Exclusion Criteria: Not having enough information recorded in the clinical history for the essential measurement variables To have taken part in other study in the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacological treatments used in Spain by Psychiatrists in the management of bipolar depressive episodes in first and second line |  | Last two bipolar episodes recorded in tha patient's clinical history | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non pharmacological treatments used in Spain by Psychiatrists in the management of bipolar depressive episodes in first and second line |  | Last two bipolar episodes recorded in tha patient's clinical history | 
| Description of the course of the patients' bipolar disorder |  | Course of the disorder recorded in the patient's clinical history | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bipolar depression Treatment